Autocrine signaling
From Proteopedia
(Difference between revisions)
Line 9: | Line 9: | ||
''Interleukin 1'' | ''Interleukin 1'' | ||
- | + | *[[Interleukins]] | |
An example of an autocrine agent is the cytokine interleukin-1 in monocytes (see [[Interleukin]]). When interleukin-1 is produced in response to external stimuli, it can bind to cell-surface receptors on the same cell that produced it (see [[Interleukin receptors]]). | An example of an autocrine agent is the cytokine interleukin-1 in monocytes (see [[Interleukin]]). When interleukin-1 is produced in response to external stimuli, it can bind to cell-surface receptors on the same cell that produced it (see [[Interleukin receptors]]). | ||
'''Interleukin 6''' | '''Interleukin 6''' | ||
- | + | ||
+ | |||
Several studies have outlined the importance of autocrine IL-6 signaling in lung and breast cancers. For example, one group found a positive correlation between persistently activated tyrosine-phosphorylated [[Stepler sandbox STAT3|STAT3]] (pSTAT3), found in 50% of lung adenocarcinomas, and IL-6. Further investigation revealed that mutant [[EGFR]] could activate the oncogenic STAT3 pathway via upregulated IL-6 autocrine signaling. Similarly, HER2 overexpression occurs in approximately a quarter of breast cancers and correlates with poor prognosis. Recent research revealed that IL-6 secretion induced by [[HER2]] overexpression activated STAT3 and altered gene expression, resulting in an autocrine loop of IL-6/STAT3 expression. Both mouse and human in vivo models of HER2-overexpressing breast cancers relied critically on this HER2–IL-6–STAT3 signaling pathway. | Several studies have outlined the importance of autocrine IL-6 signaling in lung and breast cancers. For example, one group found a positive correlation between persistently activated tyrosine-phosphorylated [[Stepler sandbox STAT3|STAT3]] (pSTAT3), found in 50% of lung adenocarcinomas, and IL-6. Further investigation revealed that mutant [[EGFR]] could activate the oncogenic STAT3 pathway via upregulated IL-6 autocrine signaling. Similarly, HER2 overexpression occurs in approximately a quarter of breast cancers and correlates with poor prognosis. Recent research revealed that IL-6 secretion induced by [[HER2]] overexpression activated STAT3 and altered gene expression, resulting in an autocrine loop of IL-6/STAT3 expression. Both mouse and human in vivo models of HER2-overexpressing breast cancers relied critically on this HER2–IL-6–STAT3 signaling pathway. | ||
- | + | ||
+ | ''Interleukin 7'' | ||
+ | |||
+ | A study demonstrates how the autocrine production of the IL-7 cytokine mediated by T-cell acute lymphoblastic leukemia (T-ALL) can be involved in the oncogenic development of T-ALL and offer novel insights into T-ALL spreading. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 06:47, 8 May 2022
|